.png)
Ana Hennino is at the origin of the project, she completed her PhD as an ENS student in Immunology at the INSERM in Lyon in 2001. She developed during PhD studies expertise in molecular mechanisms involved in apoptosis in B cell compartment and identified c-FLIP as a key regulator of the apoptosis of B cells in the germinal center.
Through her post-doctoral studies in the field of immunology of allergy she demonstrated an important role of the CD8+ T cell response at the initiation of the skin-allergic immune response. Since 2014, her research in CancerResearch Center Lyon focuses on the regulation of the immune response by the stromal compartment in the context of autoimmunity and cancer.
Pierre-Olivier is passionate about innovation in the field of health. For more than 20 years, he has accompanied, co-founded and managed numerous companies providing new therapeutic solutions in order to better treat patients. He has succeeded in signing numerous licensing and partnership agreements with major players in the life sciences, and in raising funds from professional investors and public markets.He was notably co-founder and director of Erytech Pharma, Chairman of Axoltis and Chairman of France Biotech, the French association of innovative companies in the life sciences.
Pierre-Olivier holds a Master Degree in Strategy & Finance, and another one in Management of Pharmaceutical Industry from IAE Lyon University.
20 years of experience as Entrepreneur, investor and et consultant in biotech-healthcare field
President TransCure Bioservices.
Co-founder, former CEO Indicia, former President MabDesign.
20 years or experience as Entrepreneur, investor and consultant in biotech-healthcare field.
CEO Axoltis.
Co-founder and former CEO/CSO Erytech Pharma.
